Loading
Humana Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 25 Feb 2026.
Humana Inc: what insiders have been doing
Humana Inc, classified in the Healthcare & Pharma sector, is a listed company based in Louisville, United States, founded in 1961. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Humana Inc logged 27 filings by 16 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €127k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €127k, the purchase published on 25 February 2026 by Shetty Sanjay K is the largest of the period. On the buying side, the filings list 1 chief executive among the declarants.
For context, the typical company on the same exchange (median of 5,813 companies) published 19 filings over the same period, against 27 filings here. Our records for Humana Inc go back to 2016, with 3 purchases and 6 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 129.66 bn USD of revenue and 1.19 bn USD of net income and a dividend of 3.54 USD per share.
The most recent open-market purchase was published on 25 February 2026, 235 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
187
Thresholds
n/a
Buy Volume
€2M
3 ops. · all time
Sell Volume
€10M
6 ops. · all time
Who traded when
BuySaleJames A. Rechtin1 buy
Sanjay K. Shetty1 buy
Timothy S. Huval1 sale
Since the insiders bought
- +63.9%Entry US$186.83 · Close at T+90 US$306.27
- +23.7%Entry US$247.34 · Close at T+365 US$306.00
- -30.5%Entry US$368.08 · Close at T+365 US$255.91
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Humana Inc Buy (bullish), based on 24 analysts. Average price target: US$465.13.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,954 of 24,166 companies
38.2
score / 100
Value40
Quality37
FCF yld0.8%
Earn yld2.4%
EV/EBITDA17.2x
ROE6.9%
Gross mgn·
Net mgn0.9%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$432.20
Analyst consensus
24 analystsBuy
US$280.00Target US$465.13(+8%)US$596.00
Income statement
RevenueUS$129.7B
EBITDAUS$3.6B3% margin
Net incomeUS$1.2B0.9% margin
Valuation
PER (trailing)40.9x
PER (forward)25.3x
P/Book2.7x
Beta0.74
Balance sheet & cash
Market capUS$51.9B
Total debtUS$12.4B
Free Cash FlowUS$375M
Debt / Equity76%
Profitability & ownership
ROE6.9%
ROA3.9%
% insiders0.2%
% institutions101.0%
Last declaration on 3 September 2026
Declarations187 total
2,549 shares0Humana CommonSEC:0002151421-26-000004:0
544 shares0Humana CommonSEC:0001309344-26-000006:0
544 shares0Humana CommonSEC:0001909194-26-000005:0
401 shares@ US$175.4426.2% of flowHumana CommonSEC:0001969331-26-000004:1
887 shares0Humana CommonSEC:0001969331-26-000004:0
1,035 shares0Humana CommonSEC:0001964078-26-000002:0
1,035 shares0Humana CommonSEC:0001768291-26-000002:0
5,669 shares0Humana CommonSEC:0001936662-26-000002:0
810 shares@ US$185.20554.7% of flowHumana CommonSEC:0001969331-26-000002:0
Canonical exit: 24 May 2026 (T+90)
3,858 shares0Humana CommonSEC:0002010288-26-000002:0
1,682 shares0Humana CommonSEC:0002053625-26-000002:0
7,763 shares0Humana CommonSEC:0001748812-26-000002:0
17,031 shares0Humana CommonSEC:0002107272-26-000004:0
2,183 shares0Humana CommonSEC:0002006065-26-000002:0
766 shares0Humana CommonSEC:0001486426-26-000002:0
2,353 shares0Humana CommonSEC:0001786783-26-000002:0
766 shares0Humana CommonSEC:0001547344-26-000002:0
2,032 shares0Humana CommonSEC:0002010288-25-000003:0
1,968 shares0Humana CommonSEC:0001969331-25-000003:0
455 shares0Humana CommonSEC:0001936662-25-000005:0
1,401 shares0Humana CommonSEC:0001786783-25-000009:0
2,128 shares0Humana CommonSEC:0001748812-25-000008:0
1,194 shares0Humana CommonSEC:0002053625-25-000003:0
7,707 shares0Humana CommonSEC:0002006065-25-000003:0
2,106 shares0Humana CommonSEC:0001964078-25-000005:0
25 of 187 declarations
About Humana Inc
Humana Inc. (ticker: HUM) is a major U.S. healthcare company listed on the NYSE in the United States. The group has long been associated with health insurance and has evolved into a more integrated health and well-being platform, with a strong focus on seniors and government-sponsored programs. Founded in 1961, Humana built its franchise around medical coverage and later expanded into care coordination, clinical services, and member support. Its headquarters are in Louisville, Kentucky, and the company operates through a large network of associates and care partners across the country. ([sec.gov](https://www.sec.gov/Archives/edgar/data/49071/000110465926024400/tm266867d2_ars.pdf))
Humana’s business model is centered on Medicare Advantage plans, medical benefit administration, Medicare Part D offerings, and complementary specialty products, alongside the continued expansion of CenterWell, its care delivery and pharmacy services platform. The company also emphasizes value-based care, a strategic pillar designed to improve clinical outcomes while supporting cost discipline. In 2025, Humana reported approximately 15.0 million medical members and 4.7 million specialty members, underscoring its scale in the U.S. health insurance market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000049071/000110465926024400/tm266867d2_ars.pdf))
Read moreShow less
From a competitive standpoint, Humana remains one of the leading managed-care players in the United States, with particularly strong visibility in Medicare Advantage. Its positioning is supported by an established brand, a growing clinical footprint, and a strategy aimed at simplifying the member experience. Management has repeatedly framed the company’s mission around making the U.S. healthcare system easier to navigate and more intuitive for consumers. That approach differentiates Humana from peers that may focus more narrowly on insurance underwriting alone. ([sec.gov](https://www.sec.gov/Archives/edgar/data/49071/000110465926024400/tm266867d2_ars.pdf))
Recent developments suggest a phase of strategic recalibration rather than a simple growth-at-all-costs approach. In its first-quarter 2026 results, Humana reaffirmed full-year adjusted guidance and said it expects individual Medicare Advantage membership to grow by approximately 25% in 2026 versus 2025, driven by new sales and improved retention. The company has also continued to invest in value-based care and health-data interoperability, including new clinical partnerships and digital initiatives intended to make access to health information easier for members. For French-speaking investors, HUM is therefore best viewed as a NYSE-listed U.S. healthcare leader with meaningful regulatory exposure, but also with a clear operating lever in integrated Medicare-focused services. ([policy.humana.com](https://policy.humana.com/news-and-resources/news-press/2026/humana-reports-first-quarter-2026-financial-results--affirms-ful?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
